Pipeline
Project* |
Payload |
Target |
Profile |
Advantage |
Pre-Clinical |
Phase 1 |
|||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AT-03 | AxcynDOT | CLDN6 | First-in-Class | Tumor-specific, clinically validated target | |||||||||||||||||||||||||||||||||
| AT-06 | AxcynDOT or DuXd | DLL3 x SEZ6 | Bispecific ADC | SCLC |
|
||||||||||||||||||||||||||||||||
| AT-01 | AxcynDOT and DuXd | ROR1 | Dual Payload | Efficacy Synergy for low-expression targets |
|
||||||||||||||||||||||||||||||||
| AT-00 | AxcynDOT | HER2 | Best-in-Class | Overcome resistance |
|
||||||||||||||||||||||||||||||||
| AT-04 | Duxd | ALPP/ALPPL2 | First-in-Class | PDAC – panRAS inhibitor combination |
|
||||||||||||||||||||||||||||||||
